The injectable drug -- which was tested in 19 clinical trials involving about 2,600 people -- is a formulation of a pure, non-animal derived deoxycholic acid that helps break down fat, according to the California-based company.

The FDA typically follows the recommendations of its advisory panels. If approval is granted, Kythera said sales of ATX-101 could begin in the second half of the year, WSJ reported.